# reload+after+2024-01-22 21:46:46.186651
address1§4200 Marathon Boulevard
address2§Suite 200
city§Austin
state§TX
zip§78756
country§United States
phone§737 255 7194
fax§210 974 6901
website§https://plustherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
fullTimeEmployees§17
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Marc H. Hedrick M.B.A., M.D.', 'age': 60, 'title': 'President, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 954651, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew J. Sims CPA', 'age': 50, 'title': 'VP & CFO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 446176, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Norman D.  LaFrance FACNP, FACP, M.D.', 'age': 75, 'title': 'Chief Medical Officer & Senior VP', 'yearBorn': 1948, 'fiscalYear': 2022, 'totalPay': 637811, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Desiree  Smith', 'age': 59, 'title': 'Corporate Controller, Principal Financial & Accounting Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John K. Fraser', 'age': 62, 'title': 'Chief Scientist', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.636
priceToSalesTrailing12Months§2.1461835
currency§USD
dateShortInterest§1702598400
forwardEps§-1.93
exchange§NCM
quoteType§EQUITY
shortName§PLUS THERAPEUTICS, Inc.
longName§Plus Therapeutics, Inc.
firstTradeDateEpochUtc§994858200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bd166395-f6c5-3795-b061-111c794ae585
gmtOffSetMilliseconds§-18000000
targetHighPrice§75.0
targetLowPrice§4.0
targetMeanPrice§28.0
targetMedianPrice§21.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§1.053
grossMargins§-1.40842
ebitdaMargins§0.0
trailingPegRatio§None
